Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

While Danaher (DHR) surpasses Q3 earnings and revenue estimates, the company's performance is hurt by a decrease in the sale of COVID-related products and weak demand in the Life Sciences segment.

Danaher's (DHR) Q3 Earnings & Revenues Beat, Decline Y/Y

Danaher (NYSE:DHR)'s third quarter earnings topped Wall Street estimates on the top and bottom lines but its weak guidance saw investors retreat from the stock.   The company - which designs, manufactures and markets products and services across a range of industries including medical and industrial – reported a 10.5% year-over-year drop in revenue to $6.9 billion.

Danaher 3Q earnings beat but shares fall on disappointing outlook

Disney

Fastenal

Everyone in the business media has a suggestion or two of what stocks Warren Buffett should buy or companies Berkshire Hathaway (NYSE: BRK-A , NYSE: BRK-B ) ought to acquire. I've written several articles about Warren Buffett stocks in the past year.

Hey, Warren! 3 Stocks Buffett Should Buy Now.

Danaher Corporation (NYSE:DHR ) Q3 2023 Earnings Conference Call October 24, 2023 8:00 AM ET Company Participants John Bedford - Vice President of Investor Relations Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Financial Officer Conference Call Participants Dan Brennan - TD Cowen Vijay Kumar - Evercore ISI Scott Davis - Melius Research Michael Ryskin - Bank of America Puneet Souda - Leerink Partners Rachel Vatnsdal - JPMorgan Operator Good morning. My name is Todd, and I will be your conference facilitator today.

Danaher Corporation (DHR) Q3 2023 Earnings Call Transcript

Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Danaher (DHR) Q3 Earnings

Danaher (DHR) came out with quarterly earnings of $2.02 per share, beating the Zacks Consensus Estimate of $1.83 per share. This compares to earnings of $2.56 per share a year ago.

Danaher (DHR) Surpasses Q3 Earnings and Revenue Estimates

Danaher posts third-quarter earnings of $2.02 a share on revenue of $6.87 billion.

Danaher Tops Earnings and Revenue Estimates. The Stock Is Rising.

Avantor Inc.

Catalent

DexCom

Inspire Medical Systems Inc

Coca-Cola

Eli Lilly

Novo Nordisk

PepsiCo

Insulet

Repligen

Thermo Fisher Scientific

Walmart

Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same period.

The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan

WASHINGTON , Oct. 24, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the third quarter ended September 29, 2023.  Net earnings refer to net earnings attributable to common shareholders.

Danaher Reports Third Quarter 2023 Results

Abcam

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam announced that leading independent proxy advisor Glass Lewis recommended Abcam shareholders vote “FOR” Danaher's proposed acquisition of Abcam.

Leading Independent Proxy Advisor Glass Lewis Joins ISS in Recommending Shareholders Vote “FOR” Danaher Corporation's Proposed Acquisition of Abcam

Jonathan Milner Issues Statement Responding to the Glass Lewis Report Welcomes the Glass Lewis report's observations on the disproportionate rewards for Abcam's Executive Directors and on the identified issues with peer group valuation strategies Urges Shareholders to continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher CAMBRIDGE, England, 23 October 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc (“Abcam” or the “Company”) (NYSE: ABCM) with ownership of 6.16% of the Company, has today issued the following statement in response to a 21 October 2023 report from Glass Lewis. Jonathan Milner urges shareholders to continue to vote AGAINST the current proposed acquisition of Abcam by Danaher Corporation (NYSE: DHR) or its affiliates (“Danaher”).

Jonathan Milner Issues Statement Responding to the Glass Lewis Report

Mastercard

Taiwan Semiconductor Manufacturing

Visa

Exxon Mobil

The trillion-dollar valuation club is not an easy one to reach. In fact, a grand total of just nine companies have reached this figure to-date.

7 Stocks to Buy Before They Become the Next Trillion-Dollar Companies: October Edition

Danaher is currently rated as a hold as the stock price has not reached attractive levels yet. The demand for Danaher's products in the biopharma industry has declined due to destocking and reduced investment in the sector. Danaher's solid position and its strong competitive advantages make it a company worth considering for long-term investment.

Danaher: Short-Term Headwinds, But Long-Term Tailwinds

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam announced that leading independent proxy advisor ISS recommended that Abcam shareholders vote “FOR” Danaher's proposed acquisition of Abcam.

Leading Proxy Advisor, ISS, Recommends Shareholders Vote “FOR” Danaher Corporation's Proposed Acquisition of Abcam

Jonathan Milner Issues Statement Responding to ISS Report Urges shareholders to disregard the ISS report and continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher CAMBRIDGE, England, 16 October 2023 – Jonathan Milner, the founder and one of the largest shareholders in Abcam plc (“Abcam” or the “Company”) (NYSE: ABCM) with ownership of 6.16% of the Company, has today issued the following statement in response to a 16 October 2023 report from Institutional Shareholder Service (“ISS”). Jonathan Milner urges shareholders to continue to vote AGAINST the current proposed acquisition of Abcam by Danaher Corporation (NYSE: DHR) or its affiliates (“Danaher”).

Jonathan Milner Issues Statement Responding to ISS Report

Danaher's (DHR) Q3 results are likely to be hurt by weakness in the Biotechnology and Diagnostics segments due to a decrease in the sale of COVID-related products.

Will Diagnostic Unit Weakness Mar Danaher's (DHR) Q3 Earnings?

Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company

In an exclusive interview with Thomas Warner (TW) of Proactive London, Dr Jonathan Milner (JM), the founder of life sciences company Abcam PLC (NASDAQ:ABCM), discusses why he believes the $24 per share acquisition offer from Danaher (NYSE:DHR) severely undervalues the company. Milner criticises the timing of the deal and advises shareholders to consider whether the $5.7 billion acquisition is in their best interest.

Exlusive: Why Abcam founder believes Danaher's acquisition offer falls short

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam filed an investor presentation on the proposed sale of Abcam to Danaher and the Independent Directors mailed a letter to shareholders.

Independent Directors of Abcam Highlight Compelling Reasons for Shareholders to Support Proposed Sale to Danaher

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Abcam plc (NasdaqGS: ABCM) to Danaher Corporation (NYSE: DHR). Under the terms of the proposed transaction, shareholders of Abcam will receive $24.00 in cash for each share of Abcam that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the.

ABCAM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abcam plc - ABCM

Urges shareholders to question the scheme circular, the unacceptable Offer price and continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher Corporation

Jonathan Milner issues Open Letter to shareholders of Abcam plc

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam files and mails Scheme Circular seeking approval of acquisition of Abcam by Danaher for $24.00 per share.

Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher for $24.00 per Share

Veralto Corp

Veralto Corporation, the former Environmental & Applied Solutions segment of Danaher Corporation, has started trading as a publicly traded entity. Veralto is a $5 billion business focused on water and product quality, with 60% of sales generated from water quality services. The spinoff has resulted in Veralto commanding a premium valuation, although marking an interesting business to keep track of.

Veralto: Thoughts On The Danaher Spinoff

Danaher's revenues declined in the second quarter. Its spinoff, Veralto, began trading on Monday.

Why Shares of Danaher Are Down Monday

Danaher Corporation will complete the spin-off of its Environmental & Applied Solutions business, which will be called Veralto. Veralto is divided into two segments: Water Quality and Product Quality & Innovation, with a focus on safe drinking water and environmentally-friendly packaging. Veralto will use a derivative of Danaher's value creation framework and prioritize M&A for growth, but debt and lower credit rating may pose challenges.

News for Danaher Stock (DHR)